Hanimune Therapeutics raises $3.3M, sets sights on first food allergy treatment product

Next PostPalvella Therapeutics Announces Pipeline Update on QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ Rapamycin) for Serious, Rare Genetic Skin Diseases with No FDA-approved Therapies